The following article features coverage from the American Society of Clinical Oncology (ASCO) 2019 meeting.

Salvage radiotherapy (RT) combined with short-term androgen deprivation therapy (ADT) for men with biochemical recurrence of prostate cancer after radical prostatectomy is associated with significantly improved 10-year metastasis-free survival compared with salvage RT alone, according to follow-up data presented at the 2019 American Society of Clinical Oncology annual meeting in Chicago.

The data provide an update of findings from the GETUG-AFU 16 phase 3 randomized trial in which Christian Carrie, MD, Centre Léon Bérard, Lyon, France, and colleagues randomly assigned 743men with biochemical recurrence of prostate cancer following radical prostatectomy to receive RT alone (374 men) or RT plus short-term ADT with goserelin (369 men). After a median follow-up duration of 5.3 years, the 5-year progression-free survival rate was significantly higher among men who received RT plus ADT than among those who received RT alone (80% vs 62%), according to findings published in Lancet Oncology.

In the updated analysis, the median duration of follow-up was 112 months. Compared with RT alone, the combination treatment was associated with a significant 46% decreased risk of progression overall and a significant 53% and 44% decreased risk among low- and high-risk patients, respectively, Dr Carrie reported.

In addition, the combination arm had a significant 27% decreased risk of metastasis compared with the RT-only group, with 75% of patients in the RT plus ADT group free of metastasis at 10 years compared with 69% of those in the RT-only arm.

The authors concluded that RT plus ADT can be considered as a new standard of salvage treatment after radical prostatectomy.

Related Articles

References

Carrie C, Magné N, Burban-Provost P, et al. Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GUTUG-AFU 16 phase III randomized trial (NCT00423475). Presented at the 2019 American Society of Clinical Oncology in Chicago, May 31-June 4. Abstract 5001.

Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17:747-756.